Access the full text.
Sign up today, get DeepDyve free for 14 days.
K. Garey, M. Rege, M. Pai, Dana Mingo, K. Suda, R. Turpin, D. Bearden (2006)
Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 43 1
M. Arendrup, M. Cuenca-Estrella, J. Donnelly, W. Hope, C. Lass-Flörl, J. Rodríguez-Tudela (2011)
EUCAST technical note on posaconazole.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 17 11
(2016)
Therapeutic drug monitoring of Beredaki et al. Antimicrobial Agents and Chemotherapy April 2021 Volume 65 Issue 4 e01292-20 aac.asm.org 12 posaconazole: an update
Paolo Campoli, D. Perlin, A. Kristof, T. White, S. Filler, D. Sheppard (2013)
Pharmacokinetics of posaconazole within epithelial cells and fungi: insights into potential mechanisms of action during treatment and prophylaxis.The Journal of infectious diseases, 208 10
(2013)
Fluconazole: rationale for the EUCAST clinical breakpoints
(2020)
EUCAST definitive document E.Def 7.3.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts
M. Pfaller, S. Messer, L. Boyken, R. Hollis, C. Rice, S. Tendolkar, D. Diekema (2004)
In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program.Diagnostic microbiology and infectious disease, 48 3
Maria-Ioanna Beredaki, P. Georgiou, M. Siopi, L. Kanioura, D. Andes, M. Arendrup, J. Mouton, J. Meletiadis (2020)
Toward Harmonization of Voriconazole CLSI and EUCAST Breakpoints for Candida albicans Using a Validated In Vitro Pharmacokinetic/Pharmacodynamic ModelAntimicrobial Agents and Chemotherapy, 64
D. Skiest, J. Vázquez, G. Anstead, J. Graybill, J. Reynes, D. Ward, R. Hare, N. Boparai, R. Isaacs (2007)
Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 44 4
M. Pfaller, A. Espinel-Ingroff, L. Boyken, R. Hollis, J. Kroeger, S. Messer, S. Tendolkar, D. Diekema (2011)
Comparison of the Broth Microdilution (BMD) Method of the European Committee on Antimicrobial Susceptibility Testing with the 24-Hour CLSI BMD Method for Testing Susceptibility of Candida Species to Fluconazole, Posaconazole, and Voriconazole by Use of Epidemiological Cutoff ValuesJournal of Clinical Microbiology, 49
G. Sóczó, G. Kardos, P. McNicholas, E. Balogh, L. Gergely, I. Varga, B. Kelentey, L. Majoros (2007)
Correlation of posaconazole minimum fungicidal concentration and time kill test against nine Candida species.The Journal of antimicrobial chemotherapy, 60 5
D. Andes, M. Ogtrop (1999)
Characterization and Quantitation of the Pharmacodynamics of Fluconazole in a Neutropenic Murine Disseminated Candidiasis Infection ModelAntimicrobial Agents and Chemotherapy, 43
D. Andes (2004)
Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 7 3
J. Meletiadis, R. Al-Saigh, A. Velegraki, T. Walsh, E. Roilides, L. Zerva (2011)
Pharmacodynamic Effects of Simulated Standard Doses of Antifungal Drugs against Aspergillus Species in a New In Vitro Pharmacokinetic/Pharmacodynamic ModelAntimicrobial Agents and Chemotherapy, 56
A. Espinel-Ingroff, M. Pfaller, B. Bustamante, E. Cantón, A. Fothergill, J. Fuller, G. González, C. Lass‐Flörl, S. Lockhart, E. Martín-Mazuelos, J. Meis, M. Melhem, L. Ostrosky-Zeichner, T. Peláez, M. Szeszs, G. St-Germain, L. Bonfietti, J. Guarro, J. Turnidge (2014)
Multilaboratory Study of Epidemiological Cutoff Values for Detection of Resistance in Eight Candida Species to Fluconazole, Posaconazole, and VoriconazoleAntimicrobial Agents and Chemotherapy, 58
(2011)
European Committee on Antimicrobial Susceptibility Testing—Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST)
M. Chau, D. Kong, David Kong, S. Hal, K. Urbancic, J. Trubiano, M. Cassumbhoy, J. Wilkes, C. Cooper, J. Roberts, J. Roberts, Deborah Marriott, D. Marriott, L. Worth, L. Worth (2014)
Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014Internal Medicine Journal, 44
F. Sabatelli, Reena Patel, P. Mann, Cara Mendrick, C. Norris, R. Hare, D. Loebenberg, T. Black, P. McNicholas (2006)
In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and YeastsAntimicrobial Agents and Chemotherapy, 50
A. Cacciapuoti, M. Gurnani, J. Halpern, C. Norris, Reena Patel, D. Loebenberg (2005)
Interaction between Posaconazole and Amphotericin B in Concomitant Treatment against Candida albicans In VivoAntimicrobial Agents and Chemotherapy, 49
Xin Li, Nathaniel Brown, Andrew Chau, J. Lopez-Ribot, M. Ruesga, G. Quindós, Cara Mendrick, R. Hare, D. Loebenberg, B. Didomenico, P. McNicholas (2003)
Changes in susceptibility to posaconazole in clinical isolates of Candida albicans.The Journal of antimicrobial chemotherapy, 53 1
A. Ullmann, O. Cornely, A. Burchardt, R. Hachem, D. Kontoyiannis, K. Töpelt, Rachel Courtney, Deborah Wexler, G. Krishna, M. Martinho, Gavin Corcoran, I. Raad (2006)
Pharmacokinetics, Safety, and Efficacy of Posaconazole in Patients with Persistent Febrile Neutropenia or Refractory Invasive Fungal InfectionAntimicrobial Agents and Chemotherapy, 50
A. Katragkou, F. Tsikopoulou, E. Roilides, T. Zaoutis (2011)
Posaconazole: when and how? The clinician’s viewMycoses, 55
(2017)
Performance standards for antifungal susceptibility testing of yeasts. CLSI supplement M60
B. Dekkers, M. Bakker, K. Elst, M. Sturkenboom, Anette Veringa, L. Span, J. Alffenaar (2016)
Therapeutic Drug Monitoring of Posaconazole: an UpdateCurrent Fungal Infection Reports, 10
J. Maertens, O. Cornely, A. Ullmann, W. Heinz, G. Krishna, H. Patiño, M. Caceres, N. Kartsonis, H. Waskin, M. Robertson (2014)
Phase 1B Study of the Pharmacokinetics and Safety of Posaconazole Intravenous Solution in Patients at Risk for Invasive Fungal DiseaseAntimicrobial Agents and Chemotherapy, 58
A. Lignell, E. Löwdin, O. Cars, E. Chryssanthou, J. Sjölin (2011)
Posaconazole in Human Serum: a Greater Pharmacodynamic Effect than Predicted by the Non-Protein-Bound Serum ConcentrationAntimicrobial Agents and Chemotherapy, 55
J. Vázquez, D. Skiest, L. Nieto, R. Northland, I. Sanne, J. Gogate, W. Greaves, R. Isaacs (2006)
A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 42 8
D. Andes, K. Marchillo, R. Conklin, G. Krishna, F. Ezzet, A. Cacciapuoti, D. Loebenberg (2004)
Pharmacodynamics of a New Triazole, Posaconazole, in a Murine Model of Disseminated CandidiasisAntimicrobial Agents and Chemotherapy, 48
(2007)
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE ( CHMP ) GUIDELINE ON CONDUCT OF PHARMACOVIGILANCE FOR MEDICINES USED BY THE PAEDIATRIC POPULATION
Letícia Leonart, F. Tonin, V. Ferreira, S. Penteado, A. Wiens, F. Motta, R. Pontarolo (2017)
A network meta‐analysis of primary prophylaxis for invasive fungal infection in haematological patientsJournal of Clinical Pharmacy and Therapeutics, 42
R. Duarte, J. López-Jiménez, O. Cornely, M. Laverdière, D. Helfgott, S. Haider, P. Chandrasekar, A. Langston, J. Perfect, Lei Ma, M. Iersel, N. Connelly, N. Kartsonis, H. Waskin (2014)
Phase 1b Study of New Posaconazole Tablet for Prevention of Invasive Fungal Infections in High-Risk Patients with NeutropeniaAntimicrobial Agents and Chemotherapy, 58
M. Pfaller, D. Diekema (2012)
Progress in Antifungal Susceptibility Testing of Candida spp. by Use of Clinical and Laboratory Standards Institute Broth Microdilution Methods, 2010 to 2012Journal of Clinical Microbiology, 50
D. Andes, K. Marchillo, T. Stamstad, R. Conklin (2003)
In Vivo Pharmacokinetics and Pharmacodynamics of a New Triazole, Voriconazole, in a Murine Candidiasis ModelAntimicrobial Agents and Chemotherapy, 47
Maria-Ioanna Beredaki, P. Georgiou, M. Siopi, L. Kanioura, M. Arendrup, J. Mouton, J. Meletiadis (2019)
Voriconazole efficacy against Candida glabrata and Candida krusei: preclinical data using a validated in vitro pharmacokinetic/pharmacodynamic model.The Journal of antimicrobial chemotherapy
N. Wiederhold, L. Najvar, R. Bocanegra, W. Kirkpatrick, T. Patterson (2012)
Comparison of anidulafungin's and fluconazole's in vivo activity in neutropenic and non-neutropenic models of invasive candidiasis.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 18 2
Antimicrobial Agents and Chemotherapy – American Society For Microbiology
Published: Mar 18, 2021
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.